Cancer Immunotherapy and Immune-Related Adverse Events: Focusing on Non-Small Cell Lung Cancer
Abstract
Simple Summary Immunotherapy harnesses the power of the patient’s own immune system to target and destroy cancer cells. As an important type of immunotherapy, immune checkpoint inhibitors have changed the landscape of cancer therapy and significantly improved patient outcomes. However, only some patients respond to immunotherapy and gain benefits from the treatment. Immunotherapy may also cause inflammatory and autoimmune side effects, known as immune-related adverse events. This review discusses the development of cancer immunotherapy, the modulatory effects of tumor microenvironments on immunotherapy, the use of immune checkpoint inhibitors in non-small cell lung cancer, and the types, management, and biomarkers of immunotherapy-related side effects.